Eton Pharmaceuticals appointed Judy Matthews as CFO, succeeding James Gruber, effective June 1, 2026.
Quiver AI Summary
Eton Pharmaceuticals, Inc. has appointed Judith "Judy" M. Matthews as Executive Vice President of Accounting and Finance, effective June 1, 2026. She will succeed James Gruber as Chief Financial Officer, who will step down after a planned transition while consulting for six months. CEO Sean Brynjelsen welcomed Matthews, highlighting her extensive experience in finance within growth-focused pharmaceutical companies, which will aid Eton's growth strategy in rare diseases. Matthews previously served as CFO of Iterum Therapeutics and has over 25 years in finance leadership. Eton specializes in developing treatments for rare diseases, with several commercial products and candidates in late-stage development.
Potential Positives
- Appointment of Judith M. Matthews as Executive Vice President, Accounting and Finance, which signals a commitment to strengthening the financial leadership as the company prepares for growth.
- Judith Matthews brings over 25 years of relevant experience in finance leadership within the pharmaceutical sector, potentially enhancing the company's operational effectiveness.
- Seamless transition plan in place with outgoing CFO James Gruber remaining for six months as a consultant, ensuring continuity and stability during the leadership change.
- Company emphasizes its focus on building one of the largest rare disease portfolios in the U.S., indicating ambition and strategic growth in a specialized market.
Potential Negatives
- Transitioning to a new CFO may indicate instability or uncertainty in the company's financial leadership, which could concern investors.
- James Gruber's departure after a period of rapid growth could raise questions about the sustainability of that growth and the effectiveness of existing strategies moving forward.
- None
FAQ
Who is Judith Matthews in relation to Eton Pharmaceuticals?
Judith “Judy” M. Matthews is appointed as Executive Vice President, Accounting and Finance and will become CFO on June 1, 2026.
What is the succession plan for Eton's CFO position?
James Gruber will step down as CFO on May 31, 2026, and Judith Matthews will take over the role.
What experience does Judy Matthews bring to Eton Pharmaceuticals?
Judy Matthews has over 25 years of finance leadership experience in the pharmaceutical and biotechnology industries.
What will happen to James Gruber after he steps down?
James Gruber will remain with Eton through May 31, 2026, and then enter a six-month consulting agreement.
What is Eton Pharmaceuticals focused on developing?
Eton specializes in treatments for rare diseases and currently has ten commercial products on the market.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ETON Revenue
$ETON had revenues of $21.3M in Q4 2025. This is an increase of 78.88% from the same period in the prior year.
You can track ETON financials on Quiver Quantitative's ETON stock page.
$ETON Hedge Fund Activity
We have seen 45 institutional investors add shares of $ETON stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROYAL BANK OF CANADA removed 478,175 shares (-99.8%) from their portfolio in Q4 2025, for an estimated $8,085,939
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 298,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,039,180
- OBERWEIS ASSET MANAGEMENT INC/ added 238,940 shares (+124.2%) to their portfolio in Q4 2025, for an estimated $4,040,475
- CANNELL CAPITAL LLC removed 238,488 shares (-52.4%) from their portfolio in Q4 2025, for an estimated $4,032,832
- TWO SIGMA INVESTMENTS, LP removed 209,819 shares (-73.3%) from their portfolio in Q4 2025, for an estimated $3,548,039
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 200,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,382,000
- JPMORGAN CHASE & CO removed 165,978 shares (-47.2%) from their portfolio in Q4 2025, for an estimated $2,806,687
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ETON Price Targets
Multiple analysts have issued price targets for $ETON recently. We have seen 3 analysts offer price targets for $ETON in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Madison El-Saadi from B. Riley Securities set a target price of $31.0 on 03/20/2026
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $52.0 on 03/20/2026
- Chase Knickerbocker from Craig-Hallum set a target price of $35.0 on 03/20/2026
Full Release
DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith “Judy” M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026.
The Company’s current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement with Eton.
“We are pleased to welcome Judy to Eton. She brings deep experience leading finance for growth-focused pharmaceutical companies and will be a valuable addition as we enter our next phase of growth,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “On behalf of the entire Company, I want to thank James for his contributions and dedication over the last four years. He provided exceptional leadership to our finance department through a period of rapid growth and numerous product integrations.”
“Eton’s unique model and impressive execution have set it apart in the industry. I am excited to be joining the organization at such a pivotal time, and I look forward to partnering with the team on the mission to build the largest rare disease portfolio in the United States,” said Judy Matthews, Executive Vice President, Accounting and Finance.
Ms. Matthews brings more than 25 years of finance leadership experience, including significant experience at fast-growing pharmaceutical and biotechnology companies. Prior to joining Eton, she served as Chief Financial Officer of Iterum Therapeutics plc from 2015 to 2026. Previously, she was Vice President of Finance at Durata Therapeutics until its acquisition by Actavis plc.
Ms. Matthews holds a B.A. in Accounting from the University of Illinois at Urbana-Champaign and a Master of Management in Finance and Marketing from the Kellogg School of Management at Northwestern University.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI TM , INCRELEX ® , ALKINDI SPRINKLE ® , DESMODA™, GALZIN ® , HEMANGEOL ® , PKU GOLIKE ® , Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia ® , ET-700, ET-800 and ZENEO ® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com .
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E:
[email protected]
